---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-089741"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:44:53.458949+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health completes Optimization Study for ncVNS device; results due later in 2025

## Summary
- All study visits completed for patent-pending non-invasive cervical vagus nerve stimulation device.
- Initial findings reinforce importance of personalization for therapeutic efficacy; detailed results expected later this year.
- Earlier findings presented at Bioelectronic Medicine Summit on March 4, 2025.
- CEO Jennifer Ernst says breakthroughs increase confidence in novel bioelectronic approach.
- Global VNS market forecast at $21.3B by 2030; peripheral nerve stimulation segment growing at 35% CAGR.

## SEC filing metadata
- accession: 0000950170-25-089741
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025089741/0000950170-25-089741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025089741/tivc-20250625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-089741
- JSON: https://secwatch.observer/filing/0000950170-25-089741.json
- Plain text: https://secwatch.observer/filing/0000950170-25-089741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.